SCHEMBL24965992

SCHEMBL24965992

CCc1cc(C(C)(C)C)nc2ccnn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.38
KDM4E B2RXH2 1/20 0.36
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
CDK2 P24941 1/20 0.35
KCNN3 Q9UGI6 9/20 0.35
KCNN1 Q92952 2/20 0.35
KCNN2 Q9H2S1 2/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
CCNT1 O60563 3/20 0.33
CDK9 P50750 3/20 0.33
MAPT P10636 1/20 0.33
DGAT1 O75907 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21849245 0.79 KDM4E (0.34) PDE10AKDM4EKCNN3
SCHEMBL11608751 0.78 PRKAB2 (0.49) PDE10APRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL21754101 0.78 PDE10A (0.41) PDE10AKDM4ECDK2KCNN3CCNT1
SCHEMBL21849086 0.78 KDM4E (0.42) PDE10AKDM4ECDK2KCNN3KCNN1
SCHEMBL12952976 0.77 PDE10A (0.61) PDE10AKDM4EKCNN3KCNN1KCNN2
SCHEMBL27114778 0.74 CCNT1 (0.38) PDE10AKDM4ECDK2KCNN3CCNT1
SCHEMBL27116430 0.74 PDE10A (0.38) PDE10AKDM4ECDK2KCNN3CCNT1
SCHEMBL14492447 0.72 CDK2 (0.48) PDE10AKDM4ECDK2KCNN3KCNN1
SCHEMBL22131142 0.71 PRKAB2 (0.46) PDE10APRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL9911039 0.68 DGAT1 (0.34) PDE10APRKAB2PRKAG1PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 PDE10A 2875/4885KDM4E 923/4885PRKAB2 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.